Log in
Lost password
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Shares  >  Nyse  >  Merck & Co., Inc.    MRK

News SummaryMost relevantAll newsSector news 

Merck & Co., Inc. : Merck to Present at Deutsche Bank 37th Annual Health Care Conference

05/08/2012 | 08:15am US/Eastern

Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that Peter Kellogg, executive vice president and chief financial officer and Nancy Thornberry, senior vice president and franchise head for diabetes and endocrinology are scheduled to present at the Deutsche Bank 37th Annual Health Care Conference in Boston, Mass. on May 9 at 8:00 a.m. EDT. Investors, analysts, members of the media and the general public are invited to listen to a live audio webcast of the presentation at: http://www.merck.com/investors/events-and-presentations/home.html.

About Merck

Today's Merck is a global healthcare leader working to help the world be well. Merck is known as MSD outside the United States and Canada. Through our prescription medicines, vaccines, biologic therapies, and consumer care and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to healthcare through far-reaching policies, programs and partnerships. For more information, visit www.merck.com and connect with us on Twitter, Facebook and YouTube.

Forward-Looking Statement

This news release includes "forward-looking statements" within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Such statements may include, but are not limited to, statements about the benefits of the merger between Merck and Schering-Plough, including future financial and operating results, the combined company's plans, objectives, expectations and intentions and other statements that are not historical facts. Such statements are based upon the current beliefs and expectations of Merck's management and are subject to significant risks and uncertainties. Actual results may differ from those set forth in the forward-looking statements.

The following factors, among others, could cause actual results to differ from those set forth in the forward-looking statements: the possibility that all of the expected synergies from the merger of Merck and Schering-Plough will not be realized, or will not be realized within the expected time period; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; Merck's ability to accurately predict future market conditions; dependence on the effectiveness of Merck's patents and other protections for innovative products; and the exposure to litigation and/or regulatory actions.

Merck undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in Merck's 2011 Annual Report on Form 10-K and the company's other filings with the Securities and Exchange Commission (SEC) available at the SEC's Internet site (www.sec.gov).

Ron Rogers, (908) 423-6449
Carol Ferguson, (908) 423-4465

© Business Wire 2012
React to this article
Latest news on MERCK & CO., INC.
10/05 MERCK : Results from Merck’s Phase 3 Study of Investigational Chronic Hepa..
10/05 MERCK : Congratulates Awardees of 2015 Nobel Prize in Physiology or Medicine for..
10/05 Pacific trade deal adds to U.S. price quandary for biotech drugs
10/05 MERCK : Health and Human Services Department (HHS); Food and Drug Administration..
10/02 SITC : New Immunotherapy for Lung Cancer Offers Hope to Patients, SITC Reacts
10/02DJFDA Approves Merck's Keytruda for Most Common Form of Lung Cancer -- Update
10/02 MERCK : FDA expands Merck drug's approval to treat lung cancer
10/02 MERCK : FDA Approves KEYTRUDA® (pembrolizumab) for the Treatment of Patients wit..
10/02DJFDA Approves Merck's Keytruda for Most Common Form of Lung Cancer
10/02DJFDA Approves Merck's Keytruda for Lung Cancer
Duration : Period :
Merck & Co., Inc. Technical Analysis Chart | MRK | US58933Y1055 | 4-Traders
Income Statement Evolution
More Financials